Lyra Therapeutics (NASDAQ: LYRA) files Form 25 to delist from Nasdaq Capital Market

Rhea-AI Filing Summary

Lyra Therapeutics filed a Form 25 notifying removal of its Common Stock from The Nasdaq Capital Market. The company submitted the notification on April 20, 2026. The filing covers Common Stock, par value $0.001 per share, and is submitted under Section 12(b) of the Exchange Act.

Insights

Corporate Governance Analyst

Form 25 documents a delisting notification; this is administrative but may affect shareholder liquidity.

The Form 25 submission signals that the issuer has begun the process to remove its Common Stock from the Nasdaq Capital Market under Section 12(b). The filing itself does not state reasons, trading halt status, or next steps.

Stakeholders should expect subsequent filings or exchange notices describing the effective delisting date and any appeal or transfer plans; timing is not included in the excerpt.

Key Figures

Commission File Number: 001-39273 Par value: $0.001 per share Notification date: April 20, 2026

3 metrics

Commission File Number 001-39273 Form 25 cover line

Par value $0.001 per share Common Stock par value stated in the filing

Notification date April 20, 2026 Date the Form 25 was signed

Key Terms

Form 25, Section 12(b), Nasdaq Capital Market

3 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

Section 12(b) regulatory

"REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT"

Section 12(b) of the U.S. Securities Exchange Act requires securities listed on a national stock exchange to be registered with the U.S. Securities and Exchange Commission (SEC) and to follow regular public reporting and disclosure rules. For investors, a 12(b) listing generally means more routine financial updates, regulatory oversight and easier buying and selling—like a storefront that must display its inventory and prices, making it simpler to inspect and trade the product.

Nasdaq Capital Market market

"THE NASDAQ CAPITAL MARKET (Exact name of Issuer ... where security is listed)"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING

AND/OR REGISTRATION UNDER SECTION 12(b)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-39273

LYRA THERAPEUTICS, INC.

THE NASDAQ CAPITAL MARKET

(Exact name of Issuer as specified in its charter, and name of Exchange

where security is listed and/or registered)

480 Arsenal Way

Watertown, Massachusetts 02472

(617) 393-4600

(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

Common Stock, par value $0.001 per share

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

☐ 17 CFR 240.12d2-2(a)(1)

☐ 17 CFR 240.12d2-2(a)(2)

☐ 17 CFR 240.12d2-2(a)(3)

☐ 17 CFR 240.12d2-2(a)(4)

☐ Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.

☒ Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, Lyra Therapeutics, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

Date: April 20, 2026				By:		/s/ Jason Cavalier
				Name:		Jason Cavalier
				Title:		Authorized Signatory

FAQ

What does Lyra Therapeutics' Form 25 filing mean for LYRA shareholders?

It notifies the securities regulator and exchange of intent to remove LYRA common stock from Nasdaq. The filing starts the delisting process under Section 12(b) and affects where the shares will be quoted; trading and transfer details are not provided in the excerpt.

When was Lyra Therapeutics' Form 25 submitted?

The Form 25 was signed and dated April 20, 2026. That date appears on the notification signed by an authorized signatory, Jason Cavalier.

Which class of Lyra Therapeutics securities is affected by the Form 25?

The filing covers the company's Common Stock, par value $0.001 per share. No other classes or convertible instruments are mentioned in the provided excerpt.

Does the Form 25 explain why Lyra Therapeutics is delisting from Nasdaq?

No. The excerpt contains the removal notification but does not state the reason, effective date, or any planned transfer to another market or OTC trading venue.

Who signed the Form 25 for Lyra Therapeutics?

The Form 25 was signed by Jason Cavalier as an Authorized Signatory on April 20, 2026, certifying reasonable grounds to file the notification.